In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Example input: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Example output: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Example explanation: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.
Q: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Ensuring Useful Research
Expenditures is Key for Alzheimer's Act'' or the ''EUREKA Act''.

SEC. 2. AUTHORIZATION OF NATIONAL ALZHEIMER'S AND DEMENTIA RESEARCH
BREAKTHROUGH PRIZE COMPETITIONS.

Part B of title IV of the Public Health Service Act (42 U.S.C. 284
et seq.) is amended by adding at the end the following:

''SEC. 409K. NATIONAL ALZHEIMER'S AND DEMENTIA RESEARCH BREAKTHROUGH
PRIZE COMPETITIONS.

''(a) In General.--The Director of NIH, in consultation with the
Director of the National Science Foundation, the Director of the
Defense Advanced Research Projects Agency, the Commissioner of Food and
Drugs, the Director of the Intelligence Advanced Research Projects
Activity, and the heads of any other appropriate Federal agencies that
have experience in prize competitions, shall establish prize
competitions. The competitions shall be designed to achieve high-
priority breakthroughs to achieve the national goals of preventing and
treating Alzheimer's disease by 2025, enhancing quality and efficiency
of care for individuals with Alzheimer's disease, and expanding
supports for individuals with Alzheimer's disease and the family
caregivers of such individuals.
''(b) EUREKA Prize Competitions.--
''(1) In general.--The Director of NIH, in consultation
with the Director of the National Science Foundation, the
Director of the Defense Advanced Research Projects Agency, the
Commissioner of Food and Drugs, the Director of the
Intelligence Advanced Research Projects Activity, and the heads
of any other appropriate Federal agencies that have experience
in prize competitions, and when appropriate, in coordination
with private organizations, shall establish EUREKA prize
competitions to accelerate breakthroughs in the area of
Alzheimer's disease and dementia that lead to the attainment of
critical milestones set forth in the competitions. The
competitions may be in any of the following areas:
''(A) Identification and validation of non-invasive
biomarkers to inform therapeutic targeting.
''(B) Identification of scalable, non-invasive
means of early detection and diagnosis of Alzheimer's
disease.
''(C) Repurposing of a drug approved by the Food
and Drug Administration as a disease-modifying
treatment for Alzheimer's disease.
''(D) Innovations, including technological or
telemedicine, to improve care of individuals with
Alzheimer's disease or dementia and to ease the burden
of caregiving for such individuals, including cost
burdens.
''(E) Breakthroughs to overcome a significant
scientific barrier to understanding the pathology of
Alzheimer's disease.
''(F) Other Alzheimer's disease and dementia needs,
as appropriate and as determined by the Advisory
Council described in subsection (c).
''(G) Other areas, as the Director of NIH
determines appropriate.
''(2) Publication.--The Director of NIH shall publish each
competition that is offered in the Federal Register, including
the specific award amounts offered, applicable deadlines, and
other eligibility criteria.
''(3) Eligibility.--To be eligible to win a prize under
this section, an individual or private organization--
''(A) shall have registered to participate in the
competition under any rules promulgated by the Director
of NIH under paragraph (2);
''(B) shall have complied with all the requirements
under this section;
''(C) in the case of a private organization, shall
be incorporated in and maintain a primary place of
business in the United States, and in the case of an
individual, whether participating singly or in a group,
shall be a citizen or permanent resident of the United
States, unless the Director of NIH waives such
requirement with respect to an organization or
individual; and
''(D) may not be a Federal entity or Federal
employee acting within the scope of their employment.
''(c) Advisory Council.--Not later than 1 year after the date of
enactment of the EUREKA Act, the Director of NIH shall convene an
Advisory Council of nongovernmental experts in Alzheimer's disease and
dementia to devise development of EUREKA prize competitions under
subsection (b). The council shall be comprised of 8 members,
including--
''(1) 2 experts from private organizations with expertise
in managing multi-faceted prize competitions;
''(2) 2 experts in Alzheimer's disease and dementia
biomedical research;
''(3) 2 experts in Alzheimer's disease and dementia therapy
development, including individuals with expertise in designing
and executing human clinical trials; and
''(4) 2 individuals from the caregiver or patient advocacy
community.
''(d) Evaluation of Submissions.--The Director of NIH, in
consultation with the Advisory Council, shall appoint a panel of
judges, from within or outside the National Institutes of Health,
including from the private sector, to review and evaluate all
submissions for EUREKA competitions. The judging panel shall forward
recommendations to the Director of NIH and the Advisory Council. The
Director of NIH shall evaluate all submissions recommended by the
judging panel and select submissions for which the prize shall be
awarded. In reviewing submissions and selecting awardees, the Director
of NIH may seek technical assistance and expertise from other Federal
agencies or external sources, as appropriate.
''(e) Administering the Competitions.--The Director of NIH may
enter into an agreement with a private organization to administer prize
competitions, subject to the provisions of this section.
''(f) Applicability of Other Provisions.--Subsections (e), (h),
(i), and (j) of section 24 of the Stevenson-Wydler Technology
Innovation Act of 1980 shall apply to this section. In applying such
subsection (h) to this section, the reference to subsection (g) shall
be deemed to be a reference to subsection (b) of this section.
Paragraphs (2) and (3) of subsection (k) of section 24 of the
Stevenson-Wydler Technology Innovation Act of 1980 shall apply to the
appointment and functioning of the panel of judges described in
subsection (d).
''(g) Exemption From FACA.--The Federal Advisory Committee Act (5
U.S.C. App.) shall not apply to the advisory council established under
subsection (c) or the judging panel appointed under subsection (d).
''(h) Private Organizations.--In this section, the term 'private
organizations' means nongovernmental entities, including nonprofit and
for-profit entities.
''(i) Funding.--
''(1) In general.--Support for a prize competition under
this section, including financial support for the design and
administration of a prize competition or monetary contributions
or gifts of property for a prize purse, may consist of Federal
appropriated funds, funds provided by private organizations,
and individuals. The Director of NIH may solicit and accept
funds from other Federal agencies, from private organizations,
and individuals to support such prize competitions. The
Director of NIH may not give any special consideration to any
individual or private organization in return for a donation.
''(2) Authorization of appropriations.--To carry out this
section, there are authorized to be appropriated not more than
$10,000,000, for each of fiscal years 2017 through 2021. Any
funds appropriated under this paragraph shall remain available
until September 30, 2025.
''(3) Clarification.--Any funds made available through this
section shall supplement, not supplant, other funding made
available for research on Alzheimer's disease and related
dementia.''.
A:
Ensuring Useful Research Expenditures is Key for Alzheimer's Act or the EUREKA Act This bill amends the Public Health Service Act to require the National Institutes of Health (NIH) to establish EUREKA prize competitions to achieve high-priority breakthroughs in Alzheimer's disease and dementia prevention, diagnosis, treatment, and care. The NIH must: (1) convene an advisory council of nongovernmental experts in Alzheimer's disease and dementia to develop the EUREKA prize competitions, and (2) appoint a panel of judges to evaluate submissions. The council and panel are not subject to the Federal Advisory Committee Act. Support for EUREKA prize competitions may be provided by private organizations and individuals.